Dopamine receptor D1-mediated suppression of liver fibrosis via Hippo/Yes-associated protein 1 signaling in levodopa treatment

Figure 1 Evaluation of the anti-fibrosis effect of L-DOPA in carbon tetrachloride-induced liver fibrosis rat model. A: The rats were divided into four groups. On day 0, 40% carbon tetrachloride (CCl₄) was injected intraperitoneally once every three days. L-DOPA (10 mg/kg) was intraperitoneally injected daily from the 7^th to the 9^th week in the low-dose and the injection group, while L-DOPA (25 mg/kg) was intraperitoneally injected daily from the 7^th to the 9^th week in the high dose group. The intervention effect of L-DOPA on liver fibrosis throughout the entire process of fibrosis and inflammation was observed with normal saline as a control; B: Changes were visualized during the experiment, the body weight of the three groups of rats was measured and standardized to the initial weight at week 7; C: Tukey's multiple comparison tests were performed to detect the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and the ratio of AST to ALT in serum of rats in different groups. ^aP < 0.05; ^cP < 0.001; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CCl₄: Carbon tetrachloride.